Here’s Why Venture Capitalists Like Juno

Here’s Why Venture Capitalists Like Juno Play

Aug. 7 (Bloomberg) -- Juno Therapeutics Scientific Co-Founder Michael Jensen and Second Avenue Partners Co-Founder Nick Hanauer discuss the Juno’s favor with venture capitalists. They speak on “Market Makers.” (Source: Bloomberg)

blog comments powered by Disqus